JNJ-95566692 enters phase 1, with Qilu neck and neck.
ApexOnco Front Page
Recent articles
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
After Aktis's $318m flotation Eikon is a bigger proposition.
$650m buys the group rights to RemeGen’s RC148.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
